On June 4th, the kick-off meeting for the clinical trial of PA3-17—the world's inaugural autologous CD7-targeted CAR-T therapy, independently developed by Biosyntech (a company with Anke Biotechnology as a stakeholder)—took place at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences. This event signifies the official launch into the Phase I clinical trial preparation phase. This achievement represents a significant leap forward in China's indigenous cell therapy landscape for pediatric hematological conditions, heralding fresh optimism for children battling relapsed or refractory T-lymphoblastic leukemia/lymphoma. Notably, PA3-17 has already showcased exceptional efficacy in adult clinical trials, boasting an 85% objective response rate and a 95% complete remission rate with no minimal residual disease, thereby laying a robust foundation for its pediatric application development.